30 November 2023FeaturesBiotechnologyMarisa Woutersen

Scientists and IP: Avoiding the pitfalls of publishing research

Publishing scientific findings after a patent application is filed can lead to more than a few potential pitfalls as a panel at LSPN Europe last week explored.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

More on this story

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More on this story

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Panitch Schwarze brings in molecular biologist

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

FTC supports USPTO terminal disclaimer plan amid opposition

BlueAllele says rival gained $100m from Regeneron deal using patented tech

Pfizer, Moderna vow appeals after split vaccine ruling